Publication date: Jun 19, 2024
Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. According to GlobalData, Phase I drugs for Parkinsons Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalDatas report assesses how Brexanolones drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. NeuTherapeutics is headquartered in the US. For a complete picture of Brexanolones drug-specific PTSR and LoA scores, buy the report here. Premium Insights From The gold standard of business intelligence. Blending expert knowledge with cutting-edge technology, GlobalDatas unrivalled proprietary data will enable you to decode whats happening in your market. Brexanolone is under clinical development by NeuTherapeutics and currently in Phase I for Parkinsons Disease. You can make better informed decisions and gain a future-proof advantage over your competitors.
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Tropicamide |
| drug | DRUGBANK | Gold |
| pathway | REACTOME | Neurodegenerative Diseases |
| disease | MESH | neurodegenerative diseases |
| drug | DRUGBANK | gamma-Aminobutyric acid |
| disease | MESH | Alzheimer’s disease |
| drug | DRUGBANK | Spinosad |
| disease | MESH | Parkinson’s Disease |